Sara Shalin
Concepts (429)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Skin Neoplasms | 34 | 2024 | 489 | 9.460 |
Why?
| Skin Diseases | 7 | 2022 | 113 | 4.080 |
Why?
| Melanoma | 16 | 2024 | 282 | 3.960 |
Why?
| Dermatology | 9 | 2024 | 49 | 3.380 |
Why?
| Skin | 12 | 2024 | 412 | 3.210 |
Why?
| Nevus, Pigmented | 3 | 2024 | 35 | 1.960 |
Why?
| Immunohistochemistry | 18 | 2024 | 983 | 1.950 |
Why?
| Sebaceous Gland Neoplasms | 5 | 2022 | 16 | 1.840 |
Why?
| Carcinoma, Basal Cell | 5 | 2018 | 35 | 1.800 |
Why?
| Staining and Labeling | 3 | 2021 | 97 | 1.630 |
Why?
| Adenocarcinoma, Sebaceous | 3 | 2022 | 7 | 1.590 |
Why?
| Biopsy | 18 | 2024 | 591 | 1.590 |
Why?
| Nevus, Blue | 2 | 2021 | 11 | 1.400 |
Why?
| Humans | 84 | 2024 | 49863 | 1.400 |
Why?
| Melanocytes | 3 | 2021 | 38 | 1.380 |
Why?
| Neoplasms, Second Primary | 2 | 2024 | 74 | 1.290 |
Why?
| Dermatitis | 2 | 2022 | 36 | 1.270 |
Why?
| Female | 47 | 2024 | 26520 | 1.260 |
Why?
| Erythema Multiforme | 2 | 2020 | 11 | 1.210 |
Why?
| Middle Aged | 32 | 2024 | 12258 | 1.130 |
Why?
| Diagnosis, Differential | 14 | 2024 | 1038 | 1.120 |
Why?
| Aged, 80 and over | 18 | 2024 | 3132 | 1.100 |
Why?
| Vasculitis | 2 | 2024 | 29 | 1.080 |
Why?
| Vulvar Neoplasms | 3 | 2022 | 59 | 1.070 |
Why?
| Alopecia | 2 | 2024 | 39 | 1.020 |
Why?
| Herpes Simplex | 2 | 2022 | 21 | 1.010 |
Why?
| Aged | 27 | 2024 | 9434 | 0.970 |
Why?
| Sebaceous Glands | 2 | 2024 | 14 | 0.970 |
Why?
| Skin Diseases, Vascular | 1 | 2024 | 8 | 0.960 |
Why?
| Incidental Findings | 1 | 2024 | 39 | 0.940 |
Why?
| Dermatitis, Seborrheic | 1 | 2024 | 4 | 0.940 |
Why?
| Neoplasm Staging | 2 | 2024 | 748 | 0.940 |
Why?
| Sweat Gland Neoplasms | 3 | 2024 | 22 | 0.940 |
Why?
| Atrophy | 1 | 2024 | 38 | 0.930 |
Why?
| Sentinel Lymph Node Biopsy | 1 | 2024 | 117 | 0.890 |
Why?
| Adult | 24 | 2024 | 13325 | 0.890 |
Why?
| Nevus, Epithelioid and Spindle Cell | 3 | 2018 | 15 | 0.880 |
Why?
| Papillomavirus Infections | 2 | 2022 | 168 | 0.870 |
Why?
| Hyperoxaluria | 1 | 2022 | 4 | 0.850 |
Why?
| Hyperoxaluria, Primary | 1 | 2022 | 3 | 0.850 |
Why?
| Urolithiasis | 1 | 2022 | 4 | 0.850 |
Why?
| Graft vs Host Disease | 2 | 2020 | 73 | 0.850 |
Why?
| Adenoma | 2 | 2017 | 111 | 0.830 |
Why?
| Pathology | 2 | 2020 | 38 | 0.830 |
Why?
| Epidermal Cyst | 1 | 2022 | 12 | 0.820 |
Why?
| Granuloma | 2 | 2020 | 45 | 0.810 |
Why?
| Carcinoma in Situ | 1 | 2022 | 73 | 0.800 |
Why?
| Protein Kinases | 2 | 2016 | 70 | 0.790 |
Why?
| Muscle, Smooth | 1 | 2021 | 64 | 0.780 |
Why?
| Fungi | 1 | 2021 | 47 | 0.760 |
Why?
| Elastic Tissue | 2 | 2020 | 10 | 0.760 |
Why?
| Artifacts | 1 | 2021 | 53 | 0.750 |
Why?
| Epidermodysplasia Verruciformis | 1 | 2020 | 2 | 0.750 |
Why?
| Male | 32 | 2024 | 25439 | 0.750 |
Why?
| Foreign Bodies | 1 | 2021 | 64 | 0.740 |
Why?
| Cyclic AMP-Dependent Protein Kinase RIIalpha Subunit | 1 | 2020 | 2 | 0.740 |
Why?
| Histiocytoma, Benign Fibrous | 1 | 2020 | 14 | 0.730 |
Why?
| Methenamine | 1 | 2020 | 1 | 0.730 |
Why?
| Periodic Acid-Schiff Reaction | 1 | 2020 | 2 | 0.730 |
Why?
| Lichenoid Eruptions | 1 | 2020 | 3 | 0.730 |
Why?
| Oncogene Proteins, Fusion | 2 | 2020 | 56 | 0.730 |
Why?
| Kidney Failure, Chronic | 1 | 2022 | 198 | 0.730 |
Why?
| Vulvar Diseases | 1 | 2020 | 7 | 0.730 |
Why?
| Genitalia | 1 | 2020 | 11 | 0.720 |
Why?
| Uterine Cervical Dysplasia | 1 | 2020 | 49 | 0.720 |
Why?
| Lichen Sclerosus et Atrophicus | 1 | 2020 | 7 | 0.710 |
Why?
| Lymphatic Metastasis | 2 | 2020 | 226 | 0.710 |
Why?
| Syphilis | 1 | 2020 | 27 | 0.710 |
Why?
| Gynecology | 1 | 2020 | 49 | 0.700 |
Why?
| Lupus Erythematosus, Systemic | 1 | 2020 | 69 | 0.690 |
Why?
| Pseudoxanthoma Elasticum | 1 | 2019 | 4 | 0.670 |
Why?
| Pathology, Surgical | 1 | 2019 | 18 | 0.660 |
Why?
| Fibroma | 2 | 2020 | 39 | 0.640 |
Why?
| Pathology, Clinical | 4 | 2021 | 24 | 0.640 |
Why?
| Telangiectasis | 1 | 2018 | 3 | 0.620 |
Why?
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 51 | 0.610 |
Why?
| Carcinoma, Squamous Cell | 2 | 2024 | 326 | 0.610 |
Why?
| Carcinoma, Large Cell | 1 | 2017 | 15 | 0.600 |
Why?
| Carcinoma, Neuroendocrine | 1 | 2017 | 23 | 0.590 |
Why?
| Neoplasms, Multiple Primary | 1 | 2018 | 43 | 0.590 |
Why?
| Laryngeal Neoplasms | 1 | 2017 | 41 | 0.590 |
Why?
| Hidrocystoma | 1 | 2017 | 5 | 0.580 |
Why?
| Apocrine Glands | 1 | 2017 | 7 | 0.580 |
Why?
| Calcium Oxalate | 1 | 2017 | 8 | 0.580 |
Why?
| Inflammation | 2 | 2020 | 602 | 0.570 |
Why?
| Young Adult | 10 | 2024 | 4013 | 0.560 |
Why?
| Tumor Suppressor Protein p53 | 3 | 2020 | 214 | 0.530 |
Why?
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2016 | 53 | 0.520 |
Why?
| Brain Neoplasms | 2 | 2020 | 282 | 0.510 |
Why?
| Transcription Factors | 2 | 2021 | 558 | 0.510 |
Why?
| Carcinoma, Merkel Cell | 2 | 2022 | 41 | 0.510 |
Why?
| Sarcoptes scabiei | 1 | 2015 | 2 | 0.500 |
Why?
| Scabies | 1 | 2015 | 4 | 0.500 |
Why?
| Genital Diseases, Male | 1 | 2015 | 17 | 0.490 |
Why?
| Lymphangioma | 1 | 2014 | 9 | 0.490 |
Why?
| Histiocytosis, Sinus | 1 | 2015 | 14 | 0.490 |
Why?
| Scrotum | 1 | 2015 | 30 | 0.490 |
Why?
| Arm | 1 | 2014 | 47 | 0.460 |
Why?
| Acanthoma | 1 | 2013 | 2 | 0.450 |
Why?
| Fibroadenoma | 1 | 2013 | 7 | 0.450 |
Why?
| Eccrine Glands | 1 | 2013 | 11 | 0.450 |
Why?
| Nuclear Proteins | 1 | 2014 | 240 | 0.430 |
Why?
| Leuprolide | 1 | 2012 | 2 | 0.420 |
Why?
| Mucinosis, Follicular | 1 | 2012 | 3 | 0.420 |
Why?
| Drug Eruptions | 1 | 2012 | 13 | 0.410 |
Why?
| Endometriosis | 1 | 2012 | 14 | 0.410 |
Why?
| Cicatrix | 1 | 2012 | 39 | 0.410 |
Why?
| Mycosis Fungoides | 1 | 2012 | 28 | 0.410 |
Why?
| Adenocarcinoma, Clear Cell | 1 | 2012 | 34 | 0.410 |
Why?
| Antineoplastic Agents, Hormonal | 1 | 2012 | 49 | 0.400 |
Why?
| Thrombosis | 1 | 2015 | 249 | 0.400 |
Why?
| Social Media | 3 | 2018 | 98 | 0.390 |
Why?
| Dermis | 2 | 2021 | 18 | 0.380 |
Why?
| Histones | 3 | 2020 | 293 | 0.380 |
Why?
| Cesarean Section | 1 | 2012 | 159 | 0.370 |
Why?
| Vulva | 2 | 2020 | 17 | 0.370 |
Why?
| Mucous Membrane | 2 | 2020 | 28 | 0.360 |
Why?
| Muir-Torre Syndrome | 1 | 2010 | 1 | 0.350 |
Why?
| Hippocampus | 3 | 2006 | 219 | 0.340 |
Why?
| Gene Rearrangement | 2 | 2021 | 73 | 0.340 |
Why?
| Adolescent | 7 | 2022 | 6392 | 0.320 |
Why?
| Epithelioid Cells | 2 | 2020 | 13 | 0.310 |
Why?
| Mutation | 4 | 2024 | 1290 | 0.310 |
Why?
| Up-Regulation | 3 | 2020 | 448 | 0.300 |
Why?
| Dermatomycoses | 2 | 2016 | 19 | 0.280 |
Why?
| Leukemia, Myeloid, Acute | 3 | 2016 | 179 | 0.270 |
Why?
| Factor XIIIa | 2 | 2016 | 10 | 0.270 |
Why?
| Mutation, Missense | 3 | 2020 | 103 | 0.270 |
Why?
| Neuronal Plasticity | 1 | 2006 | 56 | 0.260 |
Why?
| MAP Kinase Signaling System | 1 | 2006 | 118 | 0.260 |
Why?
| Memory Disorders | 1 | 2006 | 49 | 0.260 |
Why?
| Memory | 1 | 2006 | 107 | 0.260 |
Why?
| Antifungal Agents | 3 | 2016 | 342 | 0.250 |
Why?
| Postoperative Complications | 1 | 2012 | 1000 | 0.250 |
Why?
| Signal Transduction | 2 | 2016 | 1605 | 0.250 |
Why?
| Fluorescent Antibody Technique, Direct | 1 | 2024 | 3 | 0.240 |
Why?
| Nerve Sheath Neoplasms | 1 | 2024 | 22 | 0.240 |
Why?
| Hematopoietic Stem Cell Transplantation | 3 | 2019 | 556 | 0.230 |
Why?
| Neurons | 2 | 2006 | 455 | 0.230 |
Why?
| SOXE Transcription Factors | 2 | 2021 | 4 | 0.230 |
Why?
| MART-1 Antigen | 2 | 2021 | 12 | 0.230 |
Why?
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 49 | 0.230 |
Why?
| Chickenpox | 1 | 2024 | 18 | 0.230 |
Why?
| Nevus | 1 | 2024 | 16 | 0.230 |
Why?
| Sensitivity and Specificity | 2 | 2024 | 855 | 0.230 |
Why?
| Lymphoma | 1 | 2024 | 65 | 0.230 |
Why?
| Carcinoma | 1 | 2024 | 139 | 0.220 |
Why?
| Fear | 1 | 2004 | 84 | 0.220 |
Why?
| Disease Outbreaks | 1 | 2024 | 123 | 0.210 |
Why?
| Oxalates | 1 | 2022 | 11 | 0.210 |
Why?
| Angioedema | 1 | 2022 | 9 | 0.210 |
Why?
| Demography | 1 | 2022 | 93 | 0.210 |
Why?
| Sarcoidosis | 1 | 2022 | 44 | 0.200 |
Why?
| Rhabdomyosarcoma, Alveolar | 1 | 2022 | 8 | 0.200 |
Why?
| Foot | 1 | 2022 | 41 | 0.200 |
Why?
| Prednisone | 1 | 2022 | 100 | 0.200 |
Why?
| Plant Structures | 1 | 2021 | 5 | 0.200 |
Why?
| Cotton Fiber | 1 | 2021 | 6 | 0.200 |
Why?
| Herpesvirus 2, Human | 1 | 2021 | 4 | 0.200 |
Why?
| Paper | 1 | 2021 | 15 | 0.200 |
Why?
| Lymphokines | 1 | 2021 | 20 | 0.200 |
Why?
| Herpesvirus 1, Human | 1 | 2021 | 15 | 0.200 |
Why?
| Platelet-Derived Growth Factor | 1 | 2021 | 23 | 0.200 |
Why?
| Histocytochemistry | 1 | 2021 | 47 | 0.200 |
Why?
| Dermatofibrosarcoma | 1 | 2021 | 8 | 0.190 |
Why?
| Herpesvirus 3, Human | 1 | 2021 | 28 | 0.190 |
Why?
| Hyperplasia | 1 | 2021 | 96 | 0.190 |
Why?
| Sutures | 1 | 2021 | 39 | 0.190 |
Why?
| Coloring Agents | 1 | 2021 | 67 | 0.190 |
Why?
| Animals | 10 | 2021 | 13133 | 0.190 |
Why?
| Stromal Cells | 1 | 2021 | 72 | 0.190 |
Why?
| Protein Processing, Post-Translational | 2 | 2020 | 159 | 0.190 |
Why?
| Retrospective Studies | 4 | 2024 | 6106 | 0.190 |
Why?
| Cadherins | 2 | 2019 | 64 | 0.190 |
Why?
| Chromones | 1 | 2021 | 18 | 0.190 |
Why?
| Lost to Follow-Up | 1 | 2020 | 10 | 0.190 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2020 | 822 | 0.190 |
Why?
| Oncogene Fusion | 1 | 2020 | 4 | 0.190 |
Why?
| DNA-Activated Protein Kinase | 1 | 2021 | 22 | 0.180 |
Why?
| Research Report | 1 | 2020 | 16 | 0.180 |
Why?
| Leprosy, Multibacillary | 1 | 2020 | 5 | 0.180 |
Why?
| Armadillos | 1 | 2020 | 6 | 0.180 |
Why?
| Skin Transplantation | 1 | 2021 | 43 | 0.180 |
Why?
| S100 Proteins | 2 | 2021 | 34 | 0.180 |
Why?
| Morpholines | 1 | 2021 | 67 | 0.180 |
Why?
| Histiocytes | 1 | 2020 | 10 | 0.180 |
Why?
| Neoplasms, Fibrous Tissue | 1 | 2020 | 2 | 0.180 |
Why?
| Phagocytosis | 1 | 2020 | 49 | 0.180 |
Why?
| Germ Cells | 1 | 2020 | 12 | 0.180 |
Why?
| Lymphocytes, Tumor-Infiltrating | 2 | 2018 | 75 | 0.180 |
Why?
| Graft Survival | 1 | 2021 | 151 | 0.180 |
Why?
| Ubiquitin-Protein Ligases | 1 | 2021 | 94 | 0.180 |
Why?
| Papillomaviridae | 1 | 2020 | 102 | 0.180 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2020 | 58 | 0.180 |
Why?
| Li-Fraumeni Syndrome | 1 | 2020 | 12 | 0.180 |
Why?
| Single-Cell Analysis | 1 | 2020 | 62 | 0.180 |
Why?
| Immunotherapy | 2 | 2019 | 237 | 0.170 |
Why?
| Matrix Metalloproteinase 9 | 1 | 2020 | 89 | 0.170 |
Why?
| Graft Rejection | 1 | 2021 | 168 | 0.170 |
Why?
| Consensus | 1 | 2020 | 156 | 0.170 |
Why?
| Adenocarcinoma | 1 | 2024 | 402 | 0.170 |
Why?
| Proto-Oncogene Proteins B-raf | 2 | 2017 | 79 | 0.170 |
Why?
| Elastin | 1 | 2019 | 23 | 0.170 |
Why?
| Integrin alpha Chains | 1 | 2019 | 9 | 0.160 |
Why?
| Intracranial Arteriovenous Malformations | 1 | 2019 | 29 | 0.160 |
Why?
| Disease Progression | 3 | 2020 | 822 | 0.160 |
Why?
| Cell Cycle Checkpoints | 1 | 2019 | 30 | 0.160 |
Why?
| Child | 4 | 2022 | 6838 | 0.160 |
Why?
| Melanoma, Experimental | 1 | 2019 | 40 | 0.160 |
Why?
| Arteriovenous Malformations | 1 | 2019 | 68 | 0.150 |
Why?
| DNA-Binding Proteins | 1 | 2021 | 418 | 0.150 |
Why?
| Acute Disease | 1 | 2019 | 367 | 0.150 |
Why?
| Collagen | 1 | 2019 | 209 | 0.150 |
Why?
| Cricoid Cartilage | 1 | 2017 | 11 | 0.150 |
Why?
| Proto-Oncogene Proteins c-kit | 1 | 2017 | 36 | 0.150 |
Why?
| Dilatation | 1 | 2017 | 26 | 0.150 |
Why?
| Antigens, CD | 1 | 2019 | 218 | 0.150 |
Why?
| T-Lymphocytes, Regulatory | 1 | 2018 | 86 | 0.150 |
Why?
| Practice Guidelines as Topic | 1 | 2020 | 454 | 0.150 |
Why?
| Tumor Burden | 1 | 2017 | 131 | 0.150 |
Why?
| Connective Tissue Diseases | 1 | 2017 | 16 | 0.140 |
Why?
| Tumor Escape | 1 | 2017 | 16 | 0.140 |
Why?
| Parvoviridae Infections | 1 | 2017 | 20 | 0.140 |
Why?
| Immunologic Surveillance | 1 | 2017 | 10 | 0.140 |
Why?
| Parvovirus B19, Human | 1 | 2017 | 17 | 0.140 |
Why?
| CTLA-4 Antigen | 1 | 2017 | 23 | 0.140 |
Why?
| Histone Code | 1 | 2017 | 30 | 0.140 |
Why?
| Rhizopus | 1 | 2016 | 4 | 0.140 |
Why?
| Trachea | 1 | 2017 | 52 | 0.140 |
Why?
| Sarcoma | 1 | 2018 | 66 | 0.140 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2017 | 40 | 0.140 |
Why?
| RNA, Fungal | 1 | 2016 | 21 | 0.140 |
Why?
| Mucormycosis | 1 | 2016 | 29 | 0.140 |
Why?
| Connexins | 1 | 2016 | 25 | 0.140 |
Why?
| Splenomegaly | 1 | 2016 | 11 | 0.140 |
Why?
| Ascomycota | 1 | 2016 | 9 | 0.140 |
Why?
| Angiomyoma | 1 | 2016 | 5 | 0.140 |
Why?
| Infant | 2 | 2015 | 3565 | 0.140 |
Why?
| Mice | 6 | 2021 | 5671 | 0.130 |
Why?
| Osteosarcoma | 1 | 2016 | 45 | 0.130 |
Why?
| Antineoplastic Agents, Alkylating | 1 | 2016 | 74 | 0.130 |
Why?
| Apoptosis | 3 | 2019 | 1102 | 0.130 |
Why?
| Recurrence | 2 | 2015 | 658 | 0.130 |
Why?
| Human Growth Hormone | 1 | 2016 | 50 | 0.130 |
Why?
| Candidiasis | 1 | 2016 | 114 | 0.130 |
Why?
| Lung Neoplasms | 2 | 2019 | 600 | 0.130 |
Why?
| Education, Medical, Continuing | 1 | 2016 | 68 | 0.130 |
Why?
| Cell Transformation, Neoplastic | 1 | 2016 | 180 | 0.130 |
Why?
| Dendritic Cells | 1 | 2016 | 133 | 0.130 |
Why?
| Adipocytes | 1 | 2016 | 121 | 0.130 |
Why?
| Avoidance Learning | 2 | 2006 | 16 | 0.130 |
Why?
| Hamartoma Syndrome, Multiple | 1 | 2015 | 15 | 0.130 |
Why?
| Fibrin | 1 | 2015 | 10 | 0.120 |
Why?
| Neoplastic Syndromes, Hereditary | 1 | 2015 | 16 | 0.120 |
Why?
| Lysine | 1 | 2015 | 83 | 0.120 |
Why?
| Facial Neoplasms | 1 | 2015 | 22 | 0.120 |
Why?
| WT1 Proteins | 1 | 2014 | 4 | 0.120 |
Why?
| Pigmentation Disorders | 1 | 2014 | 6 | 0.120 |
Why?
| Carcinosarcoma | 1 | 2015 | 18 | 0.120 |
Why?
| Purpura | 1 | 2014 | 7 | 0.120 |
Why?
| Keratin-20 | 1 | 2014 | 7 | 0.120 |
Why?
| Osteomyelitis | 1 | 2016 | 125 | 0.120 |
Why?
| United States | 2 | 2022 | 4870 | 0.120 |
Why?
| Herpes Zoster | 1 | 2014 | 13 | 0.120 |
Why?
| Hemangiosarcoma | 1 | 2014 | 16 | 0.120 |
Why?
| Drug Resistance, Neoplasm | 1 | 2017 | 313 | 0.120 |
Why?
| Eosinophils | 1 | 2015 | 44 | 0.120 |
Why?
| Fellowships and Scholarships | 1 | 2016 | 116 | 0.120 |
Why?
| Loss of Heterozygosity | 1 | 2015 | 77 | 0.120 |
Why?
| Patient Education as Topic | 1 | 2018 | 311 | 0.120 |
Why?
| Churg-Strauss Syndrome | 1 | 2014 | 3 | 0.120 |
Why?
| Prospective Studies | 1 | 2020 | 2341 | 0.120 |
Why?
| Tumor Suppressor Proteins | 1 | 2015 | 128 | 0.120 |
Why?
| DNA Copy Number Variations | 1 | 2015 | 108 | 0.120 |
Why?
| Mass Spectrometry | 1 | 2015 | 283 | 0.120 |
Why?
| Antigens, CD34 | 1 | 2014 | 65 | 0.120 |
Why?
| Lymphocytes | 1 | 2015 | 154 | 0.120 |
Why?
| Exanthema | 1 | 2014 | 32 | 0.120 |
Why?
| Neoplasm Proteins | 1 | 2016 | 322 | 0.110 |
Why?
| Eosinophilia | 1 | 2014 | 37 | 0.110 |
Why?
| Neutrophils | 1 | 2015 | 149 | 0.110 |
Why?
| Sarcoma, Kaposi | 1 | 2014 | 75 | 0.110 |
Why?
| Membrane Glycoproteins | 1 | 2014 | 247 | 0.110 |
Why?
| Chromosome Aberrations | 1 | 2015 | 295 | 0.110 |
Why?
| Kaplan-Meier Estimate | 3 | 2020 | 463 | 0.110 |
Why?
| Antibodies, Monoclonal | 1 | 2017 | 459 | 0.110 |
Why?
| Head and Neck Neoplasms | 1 | 2016 | 281 | 0.110 |
Why?
| Prognosis | 4 | 2019 | 1948 | 0.100 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2013 | 116 | 0.100 |
Why?
| DNA Mismatch Repair | 1 | 2012 | 16 | 0.100 |
Why?
| Treatment Outcome | 5 | 2021 | 5165 | 0.100 |
Why?
| Cell Differentiation | 1 | 2014 | 651 | 0.100 |
Why?
| Predictive Value of Tests | 1 | 2014 | 907 | 0.100 |
Why?
| Multiple Myeloma | 2 | 2016 | 2918 | 0.090 |
Why?
| Asthma | 1 | 2014 | 282 | 0.090 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 594 | 0.080 |
Why?
| Fatal Outcome | 2 | 2022 | 194 | 0.080 |
Why?
| CD8-Positive T-Lymphocytes | 2 | 2019 | 123 | 0.070 |
Why?
| Phorbol Esters | 1 | 2006 | 3 | 0.070 |
Why?
| Association Learning | 1 | 2006 | 11 | 0.070 |
Why?
| Theta Rhythm | 1 | 2006 | 10 | 0.070 |
Why?
| Child, Preschool | 1 | 2015 | 3872 | 0.070 |
Why?
| Amphotericin B | 2 | 2016 | 110 | 0.070 |
Why?
| Maze Learning | 1 | 2006 | 32 | 0.070 |
Why?
| Mice, Mutant Strains | 1 | 2006 | 71 | 0.070 |
Why?
| Isoproterenol | 1 | 2006 | 56 | 0.070 |
Why?
| Adrenergic beta-Agonists | 1 | 2006 | 41 | 0.070 |
Why?
| Protein Kinase C | 1 | 2006 | 71 | 0.070 |
Why?
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 82 | 0.070 |
Why?
| Immunocompromised Host | 2 | 2016 | 118 | 0.070 |
Why?
| Neoplasm Metastasis | 2 | 2016 | 235 | 0.060 |
Why?
| Cell Proliferation | 2 | 2019 | 999 | 0.060 |
Why?
| T-Lymphocytes | 2 | 2017 | 330 | 0.060 |
Why?
| Time Factors | 2 | 2016 | 2889 | 0.060 |
Why?
| Nerve Growth Factor | 1 | 2004 | 12 | 0.060 |
Why?
| Superior Cervical Ganglion | 1 | 2004 | 7 | 0.060 |
Why?
| Disease Notification | 1 | 2024 | 10 | 0.060 |
Why?
| Sensory Thresholds | 1 | 2004 | 17 | 0.060 |
Why?
| Intellectual Disability | 1 | 2006 | 125 | 0.060 |
Why?
| Blotting, Southern | 1 | 2004 | 42 | 0.060 |
Why?
| Exploratory Behavior | 1 | 2004 | 23 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 48 | 0.060 |
Why?
| Luminescent Proteins | 1 | 2004 | 54 | 0.060 |
Why?
| Green Fluorescent Proteins | 1 | 2004 | 91 | 0.060 |
Why?
| Shock | 1 | 2004 | 35 | 0.060 |
Why?
| Proto-Oncogene Proteins p21(ras) | 1 | 2024 | 66 | 0.060 |
Why?
| Physician's Role | 1 | 2024 | 48 | 0.060 |
Why?
| Brain | 2 | 2019 | 1313 | 0.060 |
Why?
| Mitogen-Activated Protein Kinases | 1 | 2004 | 154 | 0.060 |
Why?
| Psychomotor Performance | 1 | 2004 | 129 | 0.050 |
Why?
| Animals, Newborn | 1 | 2004 | 365 | 0.050 |
Why?
| Behavior, Animal | 1 | 2004 | 176 | 0.050 |
Why?
| Motor Activity | 1 | 2004 | 221 | 0.050 |
Why?
| Eyelids | 1 | 2022 | 29 | 0.050 |
Why?
| Blotting, Western | 1 | 2004 | 600 | 0.050 |
Why?
| Mice, Transgenic | 1 | 2004 | 541 | 0.050 |
Why?
| Desmin | 1 | 2022 | 6 | 0.050 |
Why?
| Follow-Up Studies | 2 | 2020 | 2174 | 0.050 |
Why?
| Edema | 1 | 2022 | 68 | 0.050 |
Why?
| Gene Expression | 1 | 2004 | 613 | 0.050 |
Why?
| gp100 Melanoma Antigen | 1 | 2021 | 8 | 0.050 |
Why?
| Microphthalmia-Associated Transcription Factor | 1 | 2021 | 4 | 0.050 |
Why?
| DNA, Viral | 1 | 2021 | 133 | 0.050 |
Why?
| Mycobacterium leprae | 1 | 2020 | 8 | 0.050 |
Why?
| Soil Microbiology | 1 | 2020 | 18 | 0.050 |
Why?
| In Situ Hybridization, Fluorescence | 1 | 2021 | 256 | 0.050 |
Why?
| RNA, Messenger | 1 | 2004 | 1101 | 0.050 |
Why?
| Societies, Medical | 1 | 2021 | 176 | 0.040 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 1354 | 0.040 |
Why?
| Retinoblastoma Protein | 1 | 2020 | 19 | 0.040 |
Why?
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2020 | 16 | 0.040 |
Why?
| Mice, Inbred BALB C | 1 | 2021 | 296 | 0.040 |
Why?
| Evidence-Based Medicine | 1 | 2021 | 247 | 0.040 |
Why?
| Cells, Cultured | 1 | 2004 | 1579 | 0.040 |
Why?
| Ulcer | 1 | 2020 | 22 | 0.040 |
Why?
| Radiotherapy, Adjuvant | 1 | 2020 | 60 | 0.040 |
Why?
| Rats, Sprague-Dawley | 1 | 2004 | 1574 | 0.040 |
Why?
| Antiviral Agents | 1 | 2021 | 168 | 0.040 |
Why?
| Host-Pathogen Interactions | 1 | 2021 | 136 | 0.040 |
Why?
| Germ-Line Mutation | 1 | 2020 | 61 | 0.040 |
Why?
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2020 | 61 | 0.040 |
Why?
| Malpractice | 1 | 2019 | 15 | 0.040 |
Why?
| Linear Models | 1 | 2020 | 274 | 0.040 |
Why?
| Microcirculation | 1 | 2019 | 71 | 0.040 |
Why?
| Diagnostic Errors | 1 | 2019 | 64 | 0.040 |
Why?
| Proportional Hazards Models | 1 | 2020 | 404 | 0.040 |
Why?
| Multivariate Analysis | 1 | 2020 | 577 | 0.040 |
Why?
| Fibrosis | 1 | 2019 | 178 | 0.040 |
Why?
| Survival Analysis | 1 | 2020 | 669 | 0.040 |
Why?
| Flow Cytometry | 1 | 2021 | 473 | 0.040 |
Why?
| Transcriptome | 1 | 2020 | 313 | 0.040 |
Why?
| Tumor Cells, Cultured | 1 | 2019 | 460 | 0.040 |
Why?
| Rare Diseases | 1 | 2018 | 44 | 0.040 |
Why?
| Rats | 1 | 2004 | 3293 | 0.040 |
Why?
| Larynx | 1 | 2017 | 30 | 0.040 |
Why?
| Cadaver | 1 | 2017 | 96 | 0.040 |
Why?
| Pressure | 1 | 2017 | 105 | 0.040 |
Why?
| Forkhead Transcription Factors | 1 | 2018 | 112 | 0.040 |
Why?
| Immunomodulation | 1 | 2017 | 37 | 0.040 |
Why?
| Tumor Microenvironment | 1 | 2019 | 221 | 0.040 |
Why?
| Genetic Predisposition to Disease | 1 | 2020 | 507 | 0.040 |
Why?
| Forearm | 1 | 2016 | 28 | 0.030 |
Why?
| Debridement | 1 | 2016 | 44 | 0.030 |
Why?
| Epithelial-Mesenchymal Transition | 1 | 2017 | 49 | 0.030 |
Why?
| Pilot Projects | 1 | 2019 | 700 | 0.030 |
Why?
| Blood Cell Count | 1 | 2016 | 38 | 0.030 |
Why?
| Toes | 1 | 2016 | 14 | 0.030 |
Why?
| Induction Chemotherapy | 1 | 2016 | 60 | 0.030 |
Why?
| Disease-Free Survival | 1 | 2017 | 452 | 0.030 |
Why?
| Lymphocyte Activation | 1 | 2017 | 171 | 0.030 |
Why?
| Family | 1 | 2018 | 177 | 0.030 |
Why?
| Antibiotic Prophylaxis | 1 | 2016 | 61 | 0.030 |
Why?
| Treatment Refusal | 1 | 2016 | 35 | 0.030 |
Why?
| Abscess | 1 | 2016 | 40 | 0.030 |
Why?
| Chemotherapy, Adjuvant | 1 | 2016 | 121 | 0.030 |
Why?
| Triazoles | 1 | 2016 | 111 | 0.030 |
Why?
| Cell Movement | 1 | 2017 | 245 | 0.030 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2016 | 181 | 0.030 |
Why?
| Biopsy, Needle | 1 | 2016 | 181 | 0.030 |
Why?
| Core Binding Factor Alpha 1 Subunit | 1 | 2015 | 43 | 0.030 |
Why?
| Epigenomics | 1 | 2016 | 67 | 0.030 |
Why?
| Disease Models, Animal | 1 | 2021 | 1448 | 0.030 |
Why?
| Methylation | 1 | 2015 | 118 | 0.030 |
Why?
| Proteome | 1 | 2017 | 153 | 0.030 |
Why?
| Mice, Inbred C57BL | 1 | 2021 | 1795 | 0.030 |
Why?
| Polymerase Chain Reaction | 1 | 2016 | 453 | 0.030 |
Why?
| Pedigree | 1 | 2015 | 125 | 0.030 |
Why?
| Comparative Genomic Hybridization | 1 | 2015 | 46 | 0.030 |
Why?
| Scalp | 1 | 2015 | 44 | 0.030 |
Why?
| Hyperlipidemias | 1 | 2014 | 50 | 0.030 |
Why?
| Transplantation, Autologous | 1 | 2016 | 463 | 0.030 |
Why?
| Arkansas | 1 | 2020 | 1982 | 0.030 |
Why?
| Bone Marrow | 1 | 2016 | 352 | 0.030 |
Why?
| DNA Mutational Analysis | 1 | 2015 | 176 | 0.030 |
Why?
| Reoperation | 1 | 2016 | 451 | 0.030 |
Why?
| Respiratory Function Tests | 1 | 2014 | 88 | 0.030 |
Why?
| Lipodystrophy | 1 | 2013 | 9 | 0.030 |
Why?
| Heterozygote | 1 | 2013 | 80 | 0.030 |
Why?
| Incidence | 1 | 2016 | 982 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2013 | 70 | 0.030 |
Why?
| Syndrome | 1 | 2013 | 237 | 0.030 |
Why?
| Neoplasm Recurrence, Local | 1 | 2016 | 627 | 0.030 |
Why?
| Epigenesis, Genetic | 1 | 2015 | 369 | 0.030 |
Why?
| Risk Assessment | 1 | 2016 | 1253 | 0.020 |
Why?
| Cell Line, Tumor | 1 | 2015 | 1387 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2014 | 953 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2016 | 1526 | 0.020 |
Why?
| Tomography, X-Ray Computed | 1 | 2014 | 1152 | 0.020 |
Why?
| Antineoplastic Agents | 1 | 2016 | 1173 | 0.020 |
Why?
|
|
Shalin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors  People in Profiles who have published with this person. _
Same Department
People who are also in this person's primary department.
|